0001209191-18-027937.txt : 20180503
0001209191-18-027937.hdr.sgml : 20180503
20180503203825
ACCESSION NUMBER: 0001209191-18-027937
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180501
FILED AS OF DATE: 20180503
DATE AS OF CHANGE: 20180503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schall Thomas J.
CENTRAL INDEX KEY: 0001423084
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 18805795
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ChemoCentryx, Inc.
CENTRAL INDEX KEY: 0001340652
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943254365
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 650-210-2900
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-01
0
0001340652
ChemoCentryx, Inc.
CCXI
0001423084
Schall Thomas J.
C/O CHEMOCENTRYX, INC.
850 MAUDE AVENUE
MOUNTAIN VIEW
CA
94043
1
1
0
0
President and CEO
Common Stock
2018-05-01
4
M
0
17127
6.00
A
2202121
D
Common Stock
2018-05-01
4
S
0
17127
11.0006
D
2184994
D
Common Stock
2018-05-02
4
M
0
32873
6.00
A
2217867
D
Common Stock
2018-05-02
4
S
0
32873
11.0258
D
2184994
D
Stock Option (right to buy)
6.00
2018-05-01
4
M
0
17127
D
2008-09-10
2018-09-10
Common Stock
17127
232873
D
Stock Option (right to buy)
6.00
2018-05-02
4
M
0
32873
D
2008-09-10
2018-09-10
Common Stock
32873
200000
D
Shares sold are associated with stock options that will expire in September 2018.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from $11.00 to $11.03 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from $11.00 to $11.20 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
As of May 1, 2018, and prior to this transaction, the exercised options were fully vested.
Not applicable.
/s/ Susan M. Kanaya, as Attorney-in-Fact
2018-05-03